Your browser doesn't support javascript.
loading
Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.
Lobet, Sarah; Caulet, Morgane; Paintaud, Gilles; Azzopardi, Nicolas; Desvignes, Céline; Chautard, Romain; Borg, Christophe; Capitain, Olivier; Ferru, Aurélie; Bouché, Olivier; Lecomte, Thierry; Ternant, David.
Afiliação
  • Lobet S; Inserm UMR 1069, Nutrition Croissance et Cancer, Tours University, Tours, France.
  • Caulet M; Department of Gastroenterology and Digestive Oncology, CHRU de Tours, Tours, France.
  • Paintaud G; EA4245 Transplantation, Immunologie, Inflammation, Tours University, Tours, France.
  • Azzopardi N; Plateforme Recherche, Centre Pilote de suivi Biologique des traitements par Anticorps, CHRU de Tours, Tours, France.
  • Desvignes C; PRC, INRAe UMR85, CNRS UMR7247, Tours University, Nouzilly, France.
  • Chautard R; EA4245 Transplantation, Immunologie, Inflammation, Tours University, Tours, France.
  • Borg C; Plateforme Recherche, Centre Pilote de suivi Biologique des traitements par Anticorps, CHRU de Tours, Tours, France.
  • Capitain O; Inserm UMR 1069, Nutrition Croissance et Cancer, Tours University, Tours, France.
  • Ferru A; Department of Gastroenterology and Digestive Oncology, CHRU de Tours, Tours, France.
  • Bouché O; Department of Oncology, CHU Besançon, Besançon, France.
  • Lecomte T; Department of Medical Oncology, ICO, Angers, France.
  • Ternant D; Department of Medical Oncology, CHU de Poitiers, Poitiers, France.
Br J Clin Pharmacol ; 90(4): 976-986, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38072829
ABSTRACT

AIMS:

The exposure-response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time-dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed to investigate the exposure-response relationships of bevacizumab in metastatic colorectal cancer (mCRC) patients while mitigating potential biases.

METHODS:

Bevacizumab pharmacokinetics was described using target-mediated drug disposition modelling. Relationships between target kinetics, progression-free (PFS) and overall (OS) survivals were assessed using joint pharmacokinetic and parametric hazard function models. Both prognostic-driven and response-driven potential biases were mitigated. These models evaluated the impact of increased antigen target levels, clearance and intensified dosing regimen on survival.

RESULTS:

Estimated target-mediated pharmacokinetic parameters in 130 assessed patients were baseline target levels (R0 = 8.4 nM), steady-state dissociation constant (KSS = 10 nM) and antibody-target complexes elimination constant (kint = 0.52 day-1). The distribution of R0 was significantly associated with increased baseline concentrations of carcinoembryonic antigen, circulating vascular endothelial growth factor and the presence of extrahepatic metastases. Unbound target levels (R) significantly influenced both progression and death hazard functions. Increasing baseline target levels and/or clearance values led to decreased bevacizumab unbound concentrations, increased R levels and shortened PFS and OS, while increasing bevacizumab dose led to decreased R and longer survival.

CONCLUSION:

This study is the first to demonstrate the relationship between bevacizumab concentrations, target involvement and clinical efficacy by effectively mitigating potential sources of bias. Most of the target amount may be tumoural in mCRC. Future studies should provide a more in-depth description of this relationship.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article